retatrutide triple agonist obesity phase 2 trial hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a retatrutide triple agonist glp-1 gip

These medications are approved for adults with obesity (a BMI over 30), or a BMI over 27 plus a weight-related condition like high blood pressure, high cholesterol, or diabetes

If you must be around sick individuals, wear a mask and maintain distance

The Irony of Overprocessed Foods While companies are riding the wave of GLP-1 drugs, it's ironic that the root cause of the obesity and poor nutrition these drugs aim to address lies in the overprocessed foods produced by the same industry

As generics emerge and production capacity grows, these therapies could diffuse to Asia, Latin America, and Africa in ways initially unimagined

Tatosian, D

Read on for answers to some of the most common